Newsletter | December 17, 2024
TOP 10 FROM THE EDITOR
1.
Innovation From Animals And Evolution
2.
GLP-1 Drugs Driving Big Budget Impact: PwC's Medical Cost Trend 2025
3.
New Leadership At The Cancer Research Institute
4.
A New Year At Life Science Leader
5.
A Proactive Approach To 'Unscrupulous' Patent Practices
6.
A Systems Approach To Parkinson's Disease
7.
The Good And Bad Of Copromotion
8.
Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals
9.
A Bioethicist Weighs In On Obesity Drugs
10.
Pharmaceutical Scientists' Salaries in 2023
TOP 10 GUEST COLUMNS
“Ruthless” Resourcing Rules For CEOs
By Ron Cooper, formerly of Albireo Pharma
Exploring Functional Uses Of AI In Life Sciences
By Latika Mahajan, The Smart Cube
Life Sciences M&A Outlook: Challenges And Opportunities In 2024
By David Stuart, RSM US LLP
COVID-19 Is Back: Are We "FLiRT"-ing With Another Disaster?
By David Dodd, GeoVax Labs, Inc.
USPTO Proposed 'Terminal Disclaimer' Rule Could Impact Life Science Patent Protections
By Jeffrey D. Morton, Haynes and Boone
Advice For Pharma In 2024: Buckle Up
By Al Jackson, Valuate Health
Examining The Growth Of Biopharma In Developing Countries
By Ellie Gabel, Revolutionized
How AI Is Helping Drug Developers Help Rare Disease Patients
By Helen Thackray, BioCryst
Biotech Restructuring: Leading Through Ambiguity
By Denise Mueller, Affimed
Leading With Heart: The Power Of Empathy In Leadership
By Laryssa Wozniak, Immunovant
TOP 10 INDUSTRY INSIGHTS
R&D Life Science Predictions: Exciting Trends To Watch For In 2024
By ThoughtSphere
Biopharmaceuticals: State Of The Industry
By Cytiva
SCOPE 2024: Key Takeaways From A First-Time Attendee
By Darcy Grabenstein, Citeline
Overcome The Hidden Complexities Of mRNA Process Development
By Sartorius
Insights On Cell And Gene Therapy Manufacturing
By Andelyn Biosciences
5 Ways To Recession-Proof Your Life Sciences Business
By William Tamulynas, Sikich
Early Access Programs: What They Are And How To Plan For Them
By Cencora PharmaLex
Experts Discuss AI's Future In Pharma
By Medable
A Flexible Approach To Eliminating Financial Barriers
By Danny Offenbacher, Greenphire
Johnson & Johnson To Invest $2B On New Biologics Facility In Wilson, Create 420 Jobs
By North Carolina Biotechnology Center
